Literature DB >> 21424409

[Arndt-Gottron syndrome with encephalopathy: complete recovery after immunosuppressive therapy].

H Schmidt, P Schramm, Th Fuchs, M Bähr, P Lingor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21424409     DOI: 10.1007/s00115-011-3266-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  14 in total

1.  The neurologic complications of scleromyxedema.

Authors:  J R Berger; M R Dobbs; M H Terhune; W F Maragos
Journal:  Medicine (Baltimore)       Date:  2001-09       Impact factor: 1.889

2.  Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG).

Authors:  Marissa Blum; Fredrick M Wigley; Laura K Hummers
Journal:  Medicine (Baltimore)       Date:  2008-01       Impact factor: 1.889

3.  Immunomodulation of experimental pulmonary fibrosis by intravenous immunoglobulin (IVIG).

Authors:  Vered Molina; Saleem Haj-Yahia; Inna Solodeev; Yair Levy; Miri Blank; Yehuda Shoenfeld
Journal:  Autoimmunity       Date:  2006-12       Impact factor: 2.815

4.  Plasmapheresis in a patient with scleromyxedema.

Authors:  A I Westheim; D P Lookingbill
Journal:  Arch Dermatol       Date:  1987-06

5.  [Ultrastructural findings in Arndt-Gottron's scleromyxedema].

Authors:  U Schmidt; M Zabel
Journal:  Z Hautkr       Date:  1984-06-15

6.  Encephalopathy in scleromyxedema.

Authors:  K Johkura; K Susuki; O Hasegawa; Y Kuroiwa; S Komatsumoto
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

7.  [Hashimoto's encephalopathy associated with scleromyxedema: coincidental or the overlapping of two syndromes with a possible autoimmune origin?].

Authors:  A G Caicoya; L Barco-Nebreda; J L González-Gutiérrez; J A Egido-Herrero
Journal:  Rev Neurol       Date:  2004 Oct 16-31       Impact factor: 0.870

8.  Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis.

Authors:  Pedro W Baron; Kenneth Cantos; Donald J Hillebrand; Ke-Qin Hu; Okechukwu N Ojogho; Sandra Nehlsen-Cannarella; Waldo Concepcion
Journal:  Am J Dermatopathol       Date:  2003-06       Impact factor: 1.533

9.  Treatment of scleromyxedema with melphalan.

Authors:  R B Harris; H O Perry; R A Kyle; R K Winkelmann
Journal:  Arch Dermatol       Date:  1979-03

10.  [Significance of histopathologic analysis of skin lesions in scleromyxedema. Light microscopy, electron microscopy, immunohistochemistry and immunofluorescence microscopy].

Authors:  I Krajnc; A Vizjak; A Hvala; V Jurcic; B Rozman
Journal:  Acta Med Austriaca       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.